# US 2020/0392159 A1 · Novel rapamycin derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392159 A1
- Document ID: US20200392159A1
- Status: Published application
- Kind: A1
- Application number: 17/004,434
- Filed: 2020-08-27
- Published: 2020-12-17
- Earliest claimed: 2017-09-26
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Simone BONAZZI; Michael CONNOLLY; David Jonathan GLASS; Manuel MIHALIC; Andrew William PATTERSON; Silvio ROGGO; Tea SHAVLAKADZE
- Web page: https://patentgrep.com/patent/US20200392159A1

## CPC

- C07D 498/18: Bridged systems
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 25/02: for peripheral neuropathies
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/10: Antimycotics
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The disclosure relates to compounds of formula (I) and pharmaceutically acceptable salts, and compositions thereof, wherein the substituents are as defined herein. Also provided are methods of making compounds of formula (I), and methods involving the compounds or compositions for treating disorders and diseases described herein.

## Claims

### Claim 1

A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein
R1 is selected from the group consisting of hydroxy,
and
R2 is selected from the group consisting of
wherein
m is 0, 1, 2 or 3;
n is 1, 2 or 3;
o is 1, 2, 3, 4, 5 or 6;
p is 1, 2, 3, 4 or 5
q is 1, 2, 3, 4 or 5 wherein the sum of p and q is 2, 3, 4, 5 or 6;
r is 2, 3 or 4;
s is 2, 3 or 4 wherein the sum of r and s is 4, 5 or 6;
X is O, S, NR6 or SO2;
R3 is hydrogen, C1-6alkyl, hydroxyC1-6alkyl, C3-6cycloalkylC0-6alkyl or phenylC0-6alkyl;
R4 is hydrogen;
R5 is hydrogen, hydroxy or cyano; or R4 and R5 together form ═O; and
R6 is hydrogen, C1-6alkyl, C3-6cycloalkylC0-6alkyl, phenylC0-6alkyl, C1-6alkyl-CO—, C3-8cycloalkylC0-6alkyl-CO—, C1-6alkyl-SO2— or C3-8cycloalkylC0-6alkyl-SO2—.

### Claim 2 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein
R1 is selected from the group consisting of hydroxy,
and
R2 is selected from the group consisting of
wherein
m is 0, 1, 2 or 3;
n is 1, 2 or 3;
o is 1, 2, 3, 4, 5 or 6;
p is 1, 2, 3, 4 or 5
q is 1, 2, 3, 4 or 5 wherein the sum of p and q is 2, 3, 4, 5 or 6;
r is 2, 3 or 4;
s is 2, 3 or 4 wherein the sum of r and s is 4, 5 or 6;
X is O, S, NR6 or SO2;
R3 is hydrogen, C1-6alkyl, C3-8cycloalkylC0-6alkyl or phenylC0-6alkyl;
R4 is hydrogen;
R5 is hydrogen, hydroxy or cyano; or R4 and R5 together form ═O; and
R6 is hydrogen, C1-6alkyl, C3-8cycloalkylC0-6alkyl, phenylC0-6alkyl, C1-6alkyl-CO—, C3-8cycloalkylC0-6alkyl-CO—, C1-6alkyl-SO2— or C3-6cycloalkylC0-6alkyl-SO2—.

### Claim 3 (depends on 1, 2)

The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein R1 is hydroxy.

### Claim 4 (depends on 1, 2, 3)

The compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof, wherein R2 is
and n is 1, 2 or 3.

### Claim 5 (depends on 1, 2, 3, 4)

The compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof, wherein R2 is

### Claim 6 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein said compound is selected from:
Structure

### Claim 7 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein said compound is

### Claim 8 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein said compound is

### Claim 9 (depends on 1, 2, 3, 4, 5)

The compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof, wherein said compound is

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A pharmaceutical combination comprising a therapeutically effective amount of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof and one or more therapeutically active agents.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treating a disorder or a disease mediated by the mTOR pathway in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 10, or the pharmaceutical combination of claim 11.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treating a disease or disorder in a subject, wherein the target tissue, cell or organ associated with the pathology of the disease or disorder has FKBP12 levels sufficient to inhibit mTORC1, the method comprising administering to the subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 10, or the pharmaceutical combination of claim 11.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treating a disease or disorder in a subject having, or previously determined as having, FKBP12 levels sufficient to inhibit mTORC1, the method comprising administering to the subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 10, or the pharmaceutical combination of claim 11.

### Claim 15 (depends on 12, 13, 14)

The method of any one of claims 12 to 14, wherein the disease or disorder is selected from sarcopenia, skin atrophy, cherry angiomas, seborrheic keratoses, brain atrophy, atherosclerosis, arteriosclerosis, pulmonary emphysema, osteoporosis, osteoarthritis, high blood pressure, erectile dysfunction, cataracts, macular degeneration, glaucoma, stroke, cerebrovascular disease (strokes), chronic kidney disease, diabetes-associated kidney disease, impaired hepatic function, liver fibrosis, autoimmune hepatitis, endometrial hyperplasia, metabolic dysfunction, renovascular disease, hearing loss, mobility disability, cognitive decline, tendon stiffness, heart dysfunction such as cardiac hypertrophy and/or systolic and/or diastolic dysfunction and/or hypertension, heart dysfunction which results in a decline in ejection fraction, immune senescence, Parkinson's disease, Alzheimer's disease, cancer, immune-senescence leading to cancer due to a decrease in immune-surveillance, infections due to an decline in immune-function, chronic obstructive pulmonary disease (COPD), obesity, loss of taste, loss of olfaction, arthritis, and type II diabetes including complications stemming from diabetes, such as kidney failure, blindness and neuropathy.

### Claim 16 (depends on 12, 13, 14)

The method of any one of claims 12 to 14, wherein the disorder is liver fibrosis.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 10, or the pharmaceutical combination of claim 11, wherein the disorder or disease is selected from:
Acute or chronic organ or tissue transplant rejection;
Transplant vasculopathies;
Smooth muscle cell proliferation and migration leading to vessel intimal thickening, blood vessel obstruction, obstructive coronary atherosclerosis, restenosis;
Autoimmune diseases and inflammatory conditions;
Treatment and prevention of asthma;
Multi-drug resistance (MDR);
Fungal infections;
Inflammation;
Infection;
Age-related diseases;
Neurodegenerative diseases;
Proliferative disorders, in particular cancer;
Seizures and seizure related disorders; and
Mitochondrial myopathy and mitochondrial stress.

### Claim 18 (depends on 17)

The method of claim 17, wherein the disorder is a disorder that includes the process of fibrosis and/or inflammation.

### Claim 19 (depends on 18)

The method of claim 18, wherein the disorder is selected from liver and kidney disorders.

### Claim 20 (depends on 19)

The method of claim 19, wherein the liver disorder is selected from: liver fibrosis, which occurs in end-stage liver disease; liver cirrhosis; liver failure due to toxicity; non-alcohol-associated hepatic steatosis or NASH; and alcohol-associated steatosis.

### Claim 21 (depends on 19)

The method of claim 19, wherein the kidney disorder is kidney fibrosis.

### Claim 22 (depends on 21)

The method of claim 21, wherein the kidney fibrosis occurs as a result of acute kidney injury.

### Claim 23 (depends on 19)

The method of claim 19, wherein the kidney disorder is chronic kidney disorder.

### Claim 24 (depends on 19)

The method of claim 19, wherein the kidney disorder is diabetic nephropathy.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treating an age-related disorder or disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 10, or the pharmaceutical combination of claim 11, wherein the disorder or disease is selected from: sarcopenia, skin atrophy, cherry angiomas, seborrheic keratoses, brain atrophy, atherosclerosis, arteriosclerosis, pulmonary emphysema, osteoporosis, osteoarthritis, high blood pressure, erectile dysfunction, cataracts, macular degeneration, glaucoma, stroke, cerebrovascular disease (strokes), chronic kidney disease, diabetes-associated kidney disease, impaired hepatic function, liver fibrosis, autoimmune hepatitis, endometrial hyperplasia, metabolic dysfunction, renovascular disease, hearing loss, mobility disability, cognitive decline, tendon stiffness, heart dysfunction such as cardiac hypertrophy and/or systolic and/or diastolic dysfunction and/or hypertension, heart dysfunction which results in a decline in ejection fraction, immune senescence, Parkinson's disease, Alzheimer's disease, cancer, immune-senescence leading to cancer due to a decrease in immune-surveillance, infections due to an decline in immune-function, chronic obstructive pulmonary disease (COPD), obesity, loss of taste, loss of olfaction, arthritis, and type II diabetes including complications stemming from diabetes, such as kidney failure, blindness and neuropathy.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 10, or the pharmaceutical combination of claim 11.

### Claim 27 (depends on 26)

The method of claim 26, further comprising a PD-1/PDL-1 inhibitor.

### Claim 28 (depends on 26, 27)

The method of claim 26 or 27, wherein the cancer is selected from renal cancer, renal cell carcinoma, colorectal cancer, uterine sarcoma, endometrial uterine cancer, endometrial cancer, breast cancer, ovarian cancer, cervical cancer, gastric cancer, fibro-sarcoma, pancreatic cancer, liver cancer, melanoma, leukemia, multiple myeloma, nasopharyngeal cancer, prostate cancer, lung cancer, glioblastoma, bladder cancer, mesothelioma, head cancer, rhabdomyosarcoma, sarcoma, lymphoma, and neck cancer.
